Skip to main content
. 2022 Mar 6;16(8):1761–1774. doi: 10.1002/1878-0261.13199

Fig. 3.

Fig. 3

In vivo antitumour efficacy of Nintedanib against GIST‐T1, KIT‐T670I/BaF3, GIST‐T1‐T670I and GIST‐5R mouse xenograft model. (A) Effects of nintedanib on GIST‐T1 mouse xenograft model (n = 3, independent experiments). (B) Effects of nintedanib on BaF3‐KIT‐T670I mouse allograft model (n = 5, independent experiments). (C) Effects of nintedanib on GIST‐T1‐T670I mouse xenograft model (n = 5, independent experiments). (D) Effects of nintedanib on GIST‐5R mouse xenograft model (n = 3, independent experiments). Animals were treated orally once a day with a various of dose of the drugs. Data are shown as mean ± SEM, n.s., not significant; *P‐value < 0.05; **P‐value < 0.01; ****P < 0.0001 (one‐way ANOVA).